Search clinical trials for: Maximum tolerated doses

Total 4436 results

Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

United States
Nimbus Saturn, Inc.

Recruiting

A Study of NDI 1150-101 in Patients With Solid Tumors

Solid Tumor

United States
Eutilex

Recruiting

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Solid Tumor | Prostate Cancer | Renal Cell Cancer Metastatic

United States, Korea, Republic of
Danae Hamouda, MD

Recruiting

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Advanced Solid Tumor | Advanced Pancreatic Cancer

United States
National Cancer Institute (NCI)

Recruiting

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Sarcoma | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neurofibroma, Plexiform | Leukemia, Promyelocytic, Acute

United States
Noxopharm Limited

Terminated

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

United States
University of Colorado, Denver

Active, not recruiting

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

High Grade Myelodysplastic Syndromes

United States
University of Maryland, Baltimore

Active, not recruiting

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed or Refractory Acute Myeloid Leukemia

United States
University of Maryland, Baltimore

Active, not recruiting

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Active, not recruiting

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Locally Advanced/Metastatic HER2 Positive Solid Tumors

China, United States
University of Colorado, Denver

Completed

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

NHS-IL12 for Solid Tumors

Epithelial Tumors, Malignant | Epithelial Neoplasms, Malignant | Malignant Mesenchymal Tumor

United States
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Healthy
National Cancer Institute (NCI)

Terminated

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Renal Cell Carcinoma | Renal Cell Cancer | Hereditary Leiomyomatosis

United States
Novartis Pharmaceuticals

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Metastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...

Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
National Cancer Institute (NCI)

Completed

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Sarcoma | Lymphoma | Neuroblastoma | WilmsTumor

United States
National Cancer Institute (NCI)

Withdrawn

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Sarcoma | Osteosarcoma | Brain Tumor | Neuroblastoma | Wilms Tumor

United States
National Cancer Institute (NCI)

Withdrawn

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Glioma | Pinealoma | Brain Stem Neoplasms
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Pharmacokinetics of ASP8477 | Pharmacodynamics of ASP8477

France, Belgium
Bayer

Terminated

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies

Neoplasms

Germany, United Kingdom, Norway
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Safety

Netherlands
Regeneron Pharmaceuticals

Recruiting

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

Healthy Volunteers

New Zealand
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Healthy
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Recruiting

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms

United States, Spain, Germany, Belgium, Japan, France
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (DAREONᵀᴹ-8)

Small Cell Lung Carcinoma (SCLC)

Spain, Belgium, Japan, France, Poland, Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Sichuan Enray Pharmaceutical Sciences Company

Recruiting

Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor (CNSI-Fe(II))

Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Pancreas Cancer | Thyroid Cancer | Vulva Cancer

China
NewAmsterdam Pharma

Recruiting

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (TANDEM)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | High Cholesterol | ASCVD

United States
Boehringer Ingelheim

Recruiting

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Small Cell Lung Carcinoma (SCLC)

United States, United Kingdom, Germany, France, Poland
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Obesity | Non-alcoholic Fatty Liver Disease

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

Spain, United States, Germany, Netherlands, Austria, Switzerland
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Allarity Therapeutics
Amarex Clinical Research

Recruiting

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Solid Tumors

Spain, Japan, United Kingdom, United States
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

United States, Japan, Canada
Medical College of Wisconsin
Barbara Ann Karmanos Cancer Institute; Cornerstone Pharmaceuticals

Recruiting

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma

United States
AIO-Studien-gGmbH
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer (MEFOX)

Chemo-refractory Colorectal Carcinoma

Germany

3

Subscribe